Cervical Cancer Vaccination Campaign Launched

₹600 Crore Allocated to Cervical Cancer Vaccine Rollout: A Landmark or a Long Road Ahead?

On March 2, 2026, the Union Ministry of Health and Family Welfare launched India’s first nationwide public cervical cancer vaccination campaign, targeting adolescent girls aged 9–14. Backed by a ₹600 crore allocation under the Universal Immunization Programme (UIP), this rollout will distribute the domestically manufactured quadrivalent HPV vaccine, Cervavac, free of cost. The government projects vaccination coverage for 70% of eligible girls by 2027, reducing cervical cancer incidence significantly over the next decade. Enthusiasm abounds—but so do questions about scalability and execution.

Why This Signals a Break from Earlier Patterns

India has lagged in HPV vaccination compared to global norms. While trials for Cervavac began in 2017, mass adoption was stymied by funding constraints and sporadic public health measures. Before this campaign, HPV vaccination was confined largely to private clinics or state-specific initiatives like those in Punjab and Tamil Nadu, reaching only a fraction of eligible populations. The national rollout finally acknowledges the gravity of cervical cancer, which accounts for nearly 64,000 female deaths annually—India representing one-third of cervical cancer deaths worldwide.

The shift is also symbolic of India’s growing pharmaceutical self-reliance. Cervavac, developed by the Serum Institute of India, costs only ₹200 per dose compared to imported alternatives priced upwards of ₹3,000. This affordability could democratize access, particularly in underfunded health districts. But the ₹600 crore budget over three years raises questions on whether it can realistically meet vaccination, awareness, and follow-up targets.

The Machinery: Policies, Institutions, and Provisions

The campaign is being implemented under the Universal Immunization Programme (UIP), authorized by Section 62 of the National Health Mission. UIP, established in 1985, has successfully expanded immunization against diseases like polio and measles but has struggled with newer vaccines. Cervical cancer immunization now becomes a test case for whether UIP can integrate HPV coverage without diluting primary immunization goals.

Operational responsibility lies with State and District Program Officers, who must coordinate school-based and community outreach programs. The logistical demands are vast: vaccine cold chain management, HR training, and digital health registry integration. As of 2026, less than 30% of India’s districts have fully functional vaccine cold chain systems, according to a report by the National Cold Chain Assessment Committee—a statistic that should raise alarms.

The Data Painfully Contradicts the Optimism

The Ministry expects to vaccinate 70% of 78 million eligible adolescent girls within the first phase by 2027. Yet it is questionable whether this timeline can hold. Data from the National Family Health Survey (NFHS-5) shows that even primary immunization coverage for the under-five age group varies dramatically across states. Bihar and Uttar Pradesh report less than 60% coverage, while states like Kerala exceed 90%. If geographical inequities persist, HPV vaccine distribution may tilt heavily toward urban and well-resourced states.

The ₹600 crore budget also appears insufficient. Multiply the number of doses required—two per girl—by logistical costs like transport, human resource expansion, and public awareness campaigns, and the per capita allocation stretches thin. Compare this to Australia, where government spending for similar vaccination drives exceeded $50 million annually for 15 years, ensuring school-based and catch-up campaigns reached 90% coverage.

The Uncomfortable Implementation Questions

Who tracks outcomes once vaccinations are administered? Unlike routine immunization, HPV vaccines require follow-up spin-offs: screenings for early cancer detection through Pap smears, treatment facilities for vaccine failures, and risk monitoring across regions. India currently lacks standardized cervical health screening under public programs—a glaring omission in an otherwise grand initiative.

Regulatory bottlenecks further complicate execution. Vaccine hesitancy remains an under-discussed issue. The infamous 2009 controversy surrounding HPV vaccine trials, whereby clinical ethics and consent procedures were flouted, has left lingering doubts in public perception. This mistrust could undermine uptake, especially in conservative rural settings where biological explanations of HPV transmission face cultural barriers.

Another friction point lies in center-state coordination. Public health is primarily a state subject under Schedule VII of the Indian Constitution, yet over-centralization by the Ministry of Health has often alienated state-level execution teams during UIP expansions. How this dynamics plays out during the cervical cancer campaign remains a pivotal question.

An International Comparison: Lessons from Australia

Australia’s National HPV Vaccination Program launched in 2007 and achieved an impressive 80% vaccination rate within its first decade. Two key lessons stand out. First, Australia integrated school-based vaccination alongside national awareness campaigns, which significantly boosted uptake. Second, the government ensured seamless cervical screening programs and analytics to monitor vaccine efficacy longitudinally. India’s campaign—with limited Indigenous data on population-level efficacy and scant screening rollout—offers neither.

Australia also benefits from its political stability in health policy; its vaccination strategy was immune to frequent government regime changes undermining funding priorities. India’s fragmented and politically charged federal structure often disrupts continuity.

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions